Results 281 to 290 of about 284,370 (314)
Some of the next articles are maybe not open access.
Breast Disease, 2000
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire +2 more sources
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire +2 more sources
The role of HER2 in angiogenesis
Seminars in Oncology, 2001Recent studies have established that growth factors and their receptors play an essential role in regulating the proliferation of epithelial cells. Abnormalities in the expression, structure, or activity of their proto-oncogene products contribute to the development and maintenance of the malignant phenotype.
R, Kumar, R, Yarmand-Bagheri
openaire +2 more sources
Repurposing HER2 IHC: Pan-HER2 and Low-HER2
Applied Immunohistochemistry & Molecular MorphologyThe recent clinical trials and regulatory approval of new antibody drug conjugates targeting HER2 protein (trastuzumab deruxtecan, T-DXd) has moved the bar in terms of therapy for breast cancer and other solid tumors. With new drugs and expanding indications comes a need for refined companion diagnostics.
openaire +1 more source
Seminars in Oncology, 2002
HER2/neu is a compelling cancer vaccine candidate because it is overexpressed on some cancer cells relative to normal tissues, it is known to be immunogenic in both animal models and in humans, and it is already known to be targetable by the antibody component of the immune system in the form of monoclonal antibody therapy with trastuzumab.
Teresa M, Foy +5 more
openaire +2 more sources
HER2/neu is a compelling cancer vaccine candidate because it is overexpressed on some cancer cells relative to normal tissues, it is known to be immunogenic in both animal models and in humans, and it is already known to be targetable by the antibody component of the immune system in the form of monoclonal antibody therapy with trastuzumab.
Teresa M, Foy +5 more
openaire +2 more sources
Current Medical Research and Opinion, 2001
HER2 overexpression occurs in 25% of breast cancers and seems to correlate with poor prognosis. HER2 overexpression may predict tamoxifen failure and different response rates to chemotherapeutic agents such as the taxanes and anthracyclines. The detection of HER2 and its overexpression is performed using fluorescent in situ hybridisation (FISH) and/or ...
K, Mokbel, D, Hassanally
openaire +2 more sources
HER2 overexpression occurs in 25% of breast cancers and seems to correlate with poor prognosis. HER2 overexpression may predict tamoxifen failure and different response rates to chemotherapeutic agents such as the taxanes and anthracyclines. The detection of HER2 and its overexpression is performed using fluorescent in situ hybridisation (FISH) and/or ...
K, Mokbel, D, Hassanally
openaire +2 more sources
Clinical and Translational Oncology
Investigation of 'HER2-ultralow' prevalence and the effects of HER2 status (HER2-null vs. HER2-ultralow) on prognosis in patients with early-stage (non-metastatic) breast cancer.This single-center, retrospective study analyzed 424 patients with early-stage, CerbB2 immunohistochemistry (IHC) score 0 breast cancer.
Alper Türkel +3 more
openaire +2 more sources
Investigation of 'HER2-ultralow' prevalence and the effects of HER2 status (HER2-null vs. HER2-ultralow) on prognosis in patients with early-stage (non-metastatic) breast cancer.This single-center, retrospective study analyzed 424 patients with early-stage, CerbB2 immunohistochemistry (IHC) score 0 breast cancer.
Alper Türkel +3 more
openaire +2 more sources
Clinical and Translational Oncology
HER2-overexpressing (3+) breast cancer exhibits distinct clinicopathological characteristics compared to HER2 1+ and 2+ tumors; however, differences in their molecular features remain poorly defined. This study aimed to investigate clinicopathologic and somatic alterations in breast tumors stratified by HER2 status.Ninety breast cancer patients were ...
Tamanna Thakur +6 more
openaire +2 more sources
HER2-overexpressing (3+) breast cancer exhibits distinct clinicopathological characteristics compared to HER2 1+ and 2+ tumors; however, differences in their molecular features remain poorly defined. This study aimed to investigate clinicopathologic and somatic alterations in breast tumors stratified by HER2 status.Ninety breast cancer patients were ...
Tamanna Thakur +6 more
openaire +2 more sources
2019
HER2-positive breast cancer is a particularly aggressive type of breast cancer. Indication of HER2 positivity is essential for its treatment. In addition to a few FDA-approved methods such as immunohistochemical (IHC) detection of HER2 protein expression and in situ hybridization (ISH) assessment of HER2 gene amplification, several novel methods have ...
Yun, Chen +3 more
openaire +2 more sources
HER2-positive breast cancer is a particularly aggressive type of breast cancer. Indication of HER2 positivity is essential for its treatment. In addition to a few FDA-approved methods such as immunohistochemical (IHC) detection of HER2 protein expression and in situ hybridization (ISH) assessment of HER2 gene amplification, several novel methods have ...
Yun, Chen +3 more
openaire +2 more sources
Dual HER2-targeted approaches in HER2-positive breast cancer
Breast Cancer Research and Treatment, 2011Approximately 15-20% of all breast cancers are human epidermal growth factor receptor 2 (HER2) positive, with clinical studies having validated the HER2 receptor tyrosine kinase pathway as an important therapeutic target. Presently, two HER2-targeted therapies are approved by the Food and Drug Administration for treatment of HER2-positive breast cancer:
Eugene R, Ahn, Charles L, Vogel
openaire +2 more sources
Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
Pathology - Research and PracticeHER2 (human epidermal growth factor receptor 2) status in breast cancer spans a spectrum from HER2-positive to ultra-low HER2, each category influencing prognosis and treatment decisions differently. Approximately 20 % of breast cancers overexpress HER2, correlating with aggressive disease and poorer outcomes without targeted therapy.
Sana, Ahuja +2 more
openaire +2 more sources